Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 45, 2013, Pages 18256-18261

  Ringe, Rajesh P ^a   Sanders, Rogier W ^a,b   Yasmeen, Anila ^a   Kim, Helen J ^c   Lee, Jeong Hyun ^c   Cupo, Albert ^a   Korzun, Jacob ^a   Derking, Ronald ^b   Van Montfort, Thijs ^b   Julien, Jean Philippe ^c,d   Wilson, Ian A ^c,d   Klasse, Per Johan ^a   Ward, Andrew B ^c   Moore, John P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHYMOTRYPSIN; EPITOPE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; GLYCOPROTEIN GP 41; NEUTRALIZING ANTIBODY; PROTEINASE K; SOLUBLE CD4 ANTIGEN; TRYPSIN; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ANTIGENICITY; ARTICLE; BINDING SITE; COMPARATIVE STUDY; CONFORMATION; DISULFIDE BOND; ELECTRON MICROSCOPY; ENVELOPE GENE; GEL PERMEATION CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; VIRION; VIRUS ENVELOPE; VIRUS PARTICLE; VIRUS SPIKE; VIRUS STRAIN;

AIDS VACCINES; ANTIBODIES, MONOCLONAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; MICROSCOPY, ELECTRON; MUTATION, MISSENSE; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN MULTIMERIZATION; PROTEIN SUBUNITS; ROSANILINE DYES;

EID: 84887307095     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1314351110     Document Type: Article

References (36)

1. Melikyan GB (2008) Common principles and intermediates of viral protein-mediated fusion: The HIV-1 paradigm. Retrovirology 5:111.
2. Klasse PJ (2012) The molecular basis of HIV entry. Cell Microbiol 14(8):1183-1192.
3. Zwick MB, Burton DR (2007) HIV-1 neutralization: Mechanisms and relevance to vaccine design. Curr HIV Res 5(6):608-624.
4. Walker LM, Burton DR (2010) Rational antibody-based HIV-1 vaccine design: Current approaches and future directions. Curr Opin Immunol 22(3):358-366.
5. Checkley MA, Luttge BG, Freed EO (2011) HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol 410(4):582-608.
6. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S (2008) Molecular architecture of native HIV-1 gp120 trimers. Nature 455(7209):109-113.
7. Earl PL, et al. (1994) Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol 68(5): 3015-3026.
8. Gao F, et al. (2005) Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group M consensus envelope glycoprotein. J Virol 79(2): 1154-1163.
9. Spearman P, et al.; HIV Vaccine Trials Network of NIAID (2011) A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis 203(8):1165-1173.
10. Yang X, Wyatt R, Sodroski J (2001) Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol 75(3):1165-1171.
11. Yang X, et al. (2002) Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol 76(9):4634-4642.
12. Kovacs JM, et al. (2012) HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci USA 109(30):12111-12116.
13. Binley JM, et al. (2000) A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 74(2):627-643.
14. Sanders RW, et al. (2002) Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 76(17):8875-8889.
15. Binley JM, et al. (2002) Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 76(6):2606-2616.
16. Beddows S, et al. (2007) A comparative immunogenicity study in rabbits of disulfidestabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 360(2):329-340.
17. Sanders RW, et al. (2013) A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not nonneutralizing antibodies. PLoS Pathog 9(9):e1003618.
18. Julien JP, et al. (2013) Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci USA 110(11):4351-4356.
19. Julien JP, et al. (2013) Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog 9(5):e1003342.
20. Sanders RW (2011) Clinical evaluation of a soluble trimeric HIV-1 envelope glycoprotein vaccine. Expert Rev Vaccines 10(8):1117-1120.
21. Morikawa Y, Barsov E, Jones I (1993) Legitimate and illegitimate cleavage of human immunodeficiency virus glycoproteins by furin. J Virol 67(6):3601-3604.
22. Center RJ, Lebowitz J, Leapman RD, Moss B (2004) Promoting trimerization of soluble human immunodeficiency virus type 1 (HIV-1) Env through the use of HIV-1/simian immunodeficiency virus chimeras. J Virol 78(5):2265-2276.
23. Klasse PJ, et al. (2013) Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein. J Virol 87(17):9873-9885.
24. Khayat R, et al. (2013) Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers. J Virol 87(17):9865-9872.
25. Schiffner T, et al. (2013) Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking. J Virol 87(18):10163-10172.
26. Si Z, Phan N, Kiprilov E, Sodroski J (2003) Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity. AIDS Res Hum Retroviruses 19(3):217-226.
27. Pancera M, Wyatt R (2005) Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 332(1):145-156.ET, .
28. Binley JM (2013) Topological analysis ofHIV-1 glycoproteins expressed in situ on virus surfaces reveals tighter packing but greater conformational flexibility than for soluble gp120. J Virol 87(16):9233-9249.
29. Binley JM, et al. (2003) Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J Virol 77(10):5678-5684.
30. Sanders RW, Busser E, Moore JP, Lu M, Berkhout B (2004) Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structure. AIDS Res Hum Retroviruses 20(7):742-749.
31. Guttman M, Lee KK (August 21, 2013) A functional gp41-gp120 interaction is observed in monomeric but not oligomeric, uncleaved HIV-1 Env gp140. J Virol 87(21): 11462-11475.
32. Helseth E, Olshevsky U, Furman C, Sodroski J (1991) Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J Virol 65(4):2119-2123.
33. Ferrari G, et al. (2011) An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV- 1 serum. J Virol 85(14):7029-7036.
34. Parren PW, et al. (1998) Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J Virol 72(5):3512-3519.
35. Lyumkis D, et al. (2013) Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 Env trimer. Science, in press.
36. Julien JP, et al. (2013) Crystal structure of a soluble cleaved HIV-1 envelope trimer in complex with a glycan-dependent broadly neutralizing antibody. Science, in press.